Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
Our findings suggest that KIT mutations are associated with poor response and shorter EFS in AML patients treated with VEN/HMA, highlighting the importance of KIT mutation status in risk stratification and treatment selection.
Authors
- Jing Le (ORCID: https://orcid.org/0000-0002-1473-756X)
- Bingrong Chen
- Wenxiu Shu
- Dian Jin (ORCID: https://orcid.org/0000-0002-0919-7239)
- Hui Dai (ORCID: https://orcid.org/0000-0002-1137-146X)
- Liufei Luo
- Yi Li (ORCID: https://orcid.org/0000-0002-9976-518X)
- Yuan Gong (ORCID: https://orcid.org/0000-0002-2031-0968)
- Qianqian Cai (ORCID: https://orcid.org/0009-0004-5586-6124)
- Donghua He (ORCID: https://orcid.org/0000-0002-9268-8732)
- Qianqian Yang (ORCID: https://orcid.org/0009-0008-0195-833X)
Institutions
- Ningbo Medical Center Lihuili Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1186/s40001-025-02637-w
- Citations
- 6
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 10.62
Funders
- Health Commission of Guizhou Province
- Medical and Health Research Project of Zhejiang Province